Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EDARBI vs AZILSARTAN MEDOXOMIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
Treatment of hypertension,Off-label: Diabetic nephropathy, heart failure
Treatment of hypertension (FDA-approved),Off-label: heart failure, diabetic nephropathy
EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.
40 mg orally once daily. May increase to 80 mg once daily if needed.
Approximately 20-22 hours in normal subjects; allows once-daily dosing. Half-life increases in moderate to severe hepatic impairment.
Terminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Primarily metabolized by CYP2C9 and CYP3A4; undergoes dehydrogenation and decarboxylation.
Primarily metabolized by CYP2C9 to inactive metabolites; also undergoes esterase-mediated hydrolysis to azilsartan.
Approximately 60% of dose is excreted in feces (primarily as unchanged drug) and 33% in urine (as metabolites, predominantly glucuronide conjugates).
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
High (>99% bound to serum proteins, mainly albumin).
High (>99%) to serum albumin.
Approximately 0.9 L/kg (total Vdss of about 86 L), indicating extensive distribution into tissues.
Vd of about 16 L (0.23 L/kg for a 70 kg individual); indicates limited extravascular distribution.
Absolute bioavailability is about 15% due to extensive first-pass metabolism (CYP2C9, UGT1A3).
Oral bioavailability approximately 60% under fed conditions (food reduces absorption); absolute bioavailability not determined in humans.
No dose adjustment is required for patients with mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). For patients with severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease (ESRD), caution is advised; no specific dosing recommendations are available due to limited data. Avoid use in patients undergoing dialysis.
No dose adjustment required for GFR ≥15 m L/min/1.73 m². Not recommended for GFR <15 m L/min/1.73 m² due to lack of data.
No dose adjustment is needed for mild hepatic impairment (Child-Pugh class A). For moderate hepatic impairment (Child-Pugh class B), the recommended starting dose is 40 mg once daily; maximum dose is 40 mg once daily. EDARBI should not be used in patients with severe hepatic impairment (Child-Pugh class C).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data.
Safety and efficacy in pediatric patients (<18 years) have not been established. Therefore, no dosing recommendation is provided.
Not approved for use in pediatric patients (safety and efficacy not established).
No dose adjustment is required for elderly patients (≥65 years). However, as with all patients, initiate at 40 mg once daily; consider cautious titration due to potential greater sensitivity and increased risk of hypotension.
No specific dose adjustment recommended; initiate at 40 mg once daily. Monitor renal function and blood pressure carefully due to increased sensitivity.
No FDA boxed warnings.
none
Fetal toxicity: Avoid in pregnancy; discontinue if pregnancy occurs,Hypotension in volume-depleted patients,Renal function impairment: Monitor serum creatinine and potassium,Hyperkalemia: Risk in patients with renal impairment or on potassium-sparing diuretics,Avoid use in patients with bilateral renal artery stenosis
Fetal toxicity: avoid use in pregnancy,Hypotension in volume-depleted patients,Renal impairment: monitor renal function,Hyperkalemia: monitor potassium levels
Concomitant use with aliskiren in patients with diabetes,Hypersensitivity to edarbi or any component,Pregnancy
Pregnancy (second and third trimesters),Concomitant use with aliskiren in patients with diabetes or renal impairment (e GFR <60 m L/min)
No significant food interactions. May be taken with or without food. Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, tomatoes) and salt substitutes containing potassium, especially in patients with renal impairment or those on concomitant RAAS inhibitors or potassium-sparing diuretics.
No significant food interactions; can be taken with or without food. Avoid excessive potassium intake from high-potassium foods (e.g., bananas, oranges, spinach, potatoes) or potassium-containing salt substitutes. Limit alcohol intake as it may increase blood pressure or cause dizziness.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal renal damage, oligohydramnios, and skull ossification defects. Second and third trimester exposure: Increased risk for oligohydramnios, fetal renal dysfunction, skull hypoplasia, hypotension, and anuria. Use is contraindicated in pregnancy, especially in second and third trimesters.
First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal anuria, hypotension, and death.
No data on azilsartan medoxomil (EDARBI) excretion in human milk; effects on the breastfed infant and milk production are unknown. Due to the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio unknown.
No data on presence in human milk. Manufacturer recommends discontinuing breastfeeding or drug due to potential risk. M/P ratio unknown.
EDARBI is not recommended during pregnancy; if pregnancy is detected, discontinue as soon as possible. No specific dose adjustments have been established for use in pregnancy; pharmacokinetic changes in pregnancy may alter drug exposure, but no data are available to guide dosing.
No dose adjustments during pregnancy; however, use is contraindicated in second and third trimesters due to fetal toxicity. If exposure occurs, discontinue as soon as possible.
Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) with high receptor affinity and a long half-life (~11 hours), allowing once-daily dosing. It is a prodrug that is rapidly hydrolyzed to the active moiety azilsartan. Onset of action within 2 weeks; maximum effect may take 4-6 weeks. Monitor renal function and serum potassium, especially in patients with renal impairment, diabetes, or those taking NSAIDs or potassium-sparing diuretics. Avoid use in pregnancy (category D). Dose adjustment recommended for patients with hepatic impairment (Child-Pugh class B).
Azilsartan medoxomil has the highest affinity for AT1 receptors among ARBs; may cause a rapid decrease in blood pressure in volume-depleted patients; avoid use in pregnancy (Category D); monitor renal function and serum potassium; less CYP450 interaction potential than losartan or irbesartan; can be taken without regard to meals; dose adjustment not required in mild-to-moderate hepatic impairment.
Take exactly as prescribed, usually once daily, with or without food.,Do not take if pregnant or planning to become pregnant; use effective contraception.,Avoid salt substitutes containing potassium unless approved by your doctor.,Report symptoms such as dizziness, fainting, rapid heartbeat, or signs of kidney problems (e.g., swelling, decreased urination).,If you miss a dose, take it as soon as you remember, but skip if it is almost time for the next dose. Do not double the dose.,Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen without medical advice.
Take once daily at the same time each day with or without food.,Avoid becoming dehydrated; drink adequate fluids unless directed otherwise.,Do not use if pregnant or planning to become pregnant; notify your doctor immediately if pregnancy occurs.,Do not take with aliskiren if you have diabetes or renal impairment.,Report any signs of angioedema (swelling of face, lips, tongue, difficulty breathing) or severe dizziness.,May cause dizziness, especially during first few days; avoid driving until you know how the medication affects you.,Avoid potassium supplements and salt substitutes containing potassium unless approved by your doctor.,Do not stop taking the medication without talking to your doctor.
No interactions on record
"The combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), can lead to a significant reduction in the antihypertensive and cardioprotective effects of azilsartan. NSAIDs inhibit cyclooxygenase enzymes, reducing prostaglandin synthesis, which diminishes the vasodilatory and natriuretic actions that support blood pressure control mediated by ARBs. This interaction may result in loss of blood pressure control, increased risk of renal impairment (especially in volume-depleted or elderly patients), and potential antagonism of the renal protective effects of ARBs in conditions like heart failure or chronic kidney disease."
"Oxprenolol, a non-selective beta-blocker, may attenuate the compensatory sympathetic response to Azilsartan medoxomil-induced hypotension, potentially leading to an excessive drop in blood pressure. This combination can also result in reduced cardiac output due to additive negative chronotropic effects, increasing the risk of bradycardia and heart block. Clinically, patients may experience severe hypotension, dizziness, syncope, or exacerbated heart failure symptoms."
"The combination of timolol, a non-selective beta-blocker, with azilsartan medoxomil, an angiotensin II receptor blocker (ARB), may lead to an increased risk of hypotension, bradycardia, and additive antihypertensive effects. Timolol can antagonize the compensatory sympathetic response to azilsartan-induced vasodilation, potentially resulting in excessive blood pressure reduction. Additionally, both drugs can affect renal perfusion, raising the risk of renal impairment in susceptible patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EDARBI vs AZILSARTAN MEDOXOMIL, answered by our medical review team.
EDARBI is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. AZILSARTAN MEDOXOMIL is a Angiotensin II Receptor Blocker that works by Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EDARBI and AZILSARTAN MEDOXOMIL depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EDARBI is: EDARBI (azilsartan medoxomil) is administered orally. The recommended starting dose is 40 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 80 mg once daily. Maximal antihypertensive effect is attained within 2 weeks.. The standard adult dose of AZILSARTAN MEDOXOMIL is: 40 mg orally once daily. May increase to 80 mg once daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EDARBI and AZILSARTAN MEDOXOMIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EDARBI is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure: Potential for fetal r. AZILSARTAN MEDOXOMIL is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second and third trimesters: Drugs acting directly on the renin-angiotensin system can cause fetal oligo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.